|
|
Preferred Stock OfferingsBy Preferred Stock Channel Staff, updated Thursday, March 28, 3:15 PM
Slide #260. CTI BioPharma Corp. — Preferred Stock Offering
CTI BioPharma is a biopharmaceutical company focused on the acquisition, development and commercialization of targeted therapies for blood-related cancers where there is an unmet medical need. Co. has one commercially approved product, VONJO (pacritinib), which has received approval in the U.S. by the U.S. Food and Drug Administration for the treatment of adult patients with intermediate or primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis with a platelet count below 50 x 10^9/L.
Open the CTIC Page at Preferred Stock Channel (in a new window) »
|